PI3Kδ-IN-16

CAS No. 2766437-35-6

PI3Kδ-IN-16( —— )

Catalog No. M37034 CAS No. 2766437-35-6

PI3Kδ-IN-16 is a selective and potent PI3Kδ inhibitor with anticancer and antiproliferative activity, induces cell cycle arrest and apoptosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 359 In Stock
10MG 541 In Stock
25MG 847 In Stock
50MG 1135 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PI3Kδ-IN-16
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3Kδ-IN-16 is a selective and potent PI3Kδ inhibitor with anticancer and antiproliferative activity, induces cell cycle arrest and apoptosis.
  • Description
    PI3Kδ-IN-16 is a potent and selective inhibitor of PI3Kδ. PI3Kδ-IN-16 has a strong anti-proliferative effect on cells, causing cell cycle arrest and inducing apoptosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2766437-35-6
  • Formula Weight
    406.48
  • Molecular Formula
    C22H26N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N([C@H](C(=O)N1CCN(C)CC1)C)C=2C3=C(C=CC(=C3)C=4C=CC(OC)=NC4)N=CN2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lei H, et al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments. Bioorg Chem. 2023 Sep;138:106594.?
molnova catalog
related products
  • 3BDO

    3BDO is a new mTOR activator. 3BDO inhibits autophagy.

  • SF5

    SF5 is an inhibitor of the apoptosis pathway through JNK-p53-caspase apoptotic cascade.

  • EC359

    EC359 is a potent and selective inhibitor of leukemia inhibitory factor receptor (LIFR), a potent inhibitor with anticancer activity, blocks LIF/LIFR interaction, and can be used in the study of leukemia and endometrial cancer.